Draper AJ, Madan A, Smith K, Parkinson A. Development of a non-high pressure
liquid chromatography assay to determine testosterone hydroxylase (CYP3A)
activity in human liver microsomes. Drug Metab Dispos 1998b;26:299–304.
Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of
prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24:
796–801.
Galetin A, Burt H, Gibbons L, Houston JB. Prediction of time-dependent CYP3A4
drug–drug interactions: impact of enzyme degradation, parallel elimination path-
ways, and intestinal inhibition. Drug Metab Dispos 2006;34:166–175.
Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution
in the prediction of potential drug–drug interactions. J Pharmacol Exp Ther
2005;314:180–190.
Giuliano C, Jairaj M, Zafiu CM, Laufer R. Direct determination of unbound intrinsic
drug clearance in the microsomal stability assay. Drug Metab Dispos 2005;33:1319–
1324.
Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of
ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin
Pharmacol Ther 1995;58:15–19.
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O’Mara EMJ, Hall SD.
The contribution of intestinal and hepatic CYP3A to the interaction between
midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133–143.
Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive
impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir:
the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol
1999;19:293–296.
Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ,
LeDuc BW, Zinny MA. Time course of recovery of cytochrome p450 3A function
after single doses of grapefruit juice. Clin Pharmacol Ther 2003;74:121–129.
Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol AL,
Counihan M, Roth-Schechter B, Shader RI. Kinetic and dynamic interaction study
of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther
1998a;64:661–671.
Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM,
Corbett K, Counihan M, Tobias S, Shader RI. Ketoconazole inhibition of triazolam
and alprazolam clearance: differential kinetic and dynamic consequences. Clin
Pharmacol Ther 1998b;64:237–247.
Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin
therapy in Ireland. Ir J Med Sci 2000;169:176–179.
Honig PK, Cantilena LR. Polypharmacy. Pharmacokinetic perspectives. Clin
Pharmacokinet 1994;26:85–90.
Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LRJ. Changes in the
pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with
concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231–238.
Honig PK, Worham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect
of fluconazole on the steady-state pharmacokinetics and electrocardiographic
pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993a;53:630–636.
540 ANALYSIS OFIN VITROCYTOCHROME P450 INHIBITION